IDYA
IDEAYA Biosciences, Inc.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Mar 2 ▲ 1 insider buy $1.6M at $32.96
- Apr 13 ▲ IDEAYA Biosciences announced positive Phase 2/3 clinical trial resul…
- Jun 8 ▼ IDEAYA Biosciences filed a 424B5 prospectus supplement for a $300M u…
- Jun 9 ▼ IDEAYA Biosciences is raising approximately $281.3 million in net pr…
- Jun 10 ▼ IDEAYA Biosciences completed a follow-on public offering on June 10,…
- Jun 30 ▲ 3 funds open new positions (13F)
- Jul 7 ▼ 1 insider sell $382.1K at $40.01
- Oct 6 ▼ 1 insider sell $985.4K at $37.41
- Oct 6 ▼ CEO Yujiro Hata filed a Form 144 notice of intent to sell shares of…
- Oct 16 William Blair initiates
- Oct 26 Trial readout: T-90d Trial Readout: IDE196 (Phase 3)
- Nov 2 Trial readout: T-90d Trial Readout: IDE196 (Phase 3)
Signal stack
Where each data set points today.
- InsidersMIXED
1 insider bought $1.6M at an average $32.96. 2 insiders sold $1.4M. Price is 8% below their cost.
- InstitutionsMIXED
Q2 2026: 20 added (3 new), 18 trimmed or exited. Largest new: Arrowstreet Capital, Limited Partnership $33.2M, Walleye Capital $14.4M.
- AnalystsBULLISH
20 of 22 rate it Buy or better. Median target $51.00 (+68%).
- EstimatesFALLING
Current-quarter EPS estimate −$1.133 → −$1.159 over 90 days. 2 up, 7 down in 30 days.
- Short sellersSTEADY
Short interest −9.3% to 8.24M shares. 8.9 days to cover, ≈8.5% of shares.
- TrendDOWNTREND
14% below its 50-day average.
Who's buying
13F· Q2 2026| Fund | Move | Value |
|---|---|---|
| BAKER BROS. ADVISORS LP | ADD | $186.7M |
| PRICE T ROWE ASSOCIATES INC /MD/ | ADD | $82.3M |
| ALLIANCEBERNSTEIN L.P. | DOUBLED | $54.2M |
| Fiera Capital Corp | TRIM | $53.9M |
| FEDERATED HERMES, INC. | TRIM | $53.4M |
| GOLDMAN SACHS GROUP INC | TRIM | $45.9M |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | NEW | $33.2M |
| Nuveen, LLC | ADD | $23.9M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
22 analystsPrice is inside the target range. Median implies +68%.Targets as of Nov 16, 2026.
| Date | Firm | Rating |
|---|---|---|
| Nov 10, 2026 | Mizuho MAINTAIN | Outperform |
| Nov 5, 2026 | Citigroup MAINTAIN | Buy |
| Nov 4, 2026 | RBC Capital MAINTAIN | Outperform |
| Nov 4, 2026 | Truist Securities REITERATE | Buy |
| Nov 4, 2026 | Guggenheim MAINTAIN | Buy |
| Nov 4, 2026 | Wedbush MAINTAIN | Outperform |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Hata Yujiro S President and CEO Oct 6, 2026 | SELL | $954.8K |
Hata Yujiro S President and CEO Oct 6, 2026 | EXERCISE | $113.5K |
Hata Yujiro S President and CEO Oct 6, 2026 | SELL | $30.6K |
Ruiz Briseno Andres Chief Accounting Officer Jul 7, 2026 | EXERCISE | $122.8K |
Ruiz Briseno Andres Chief Accounting Officer Jul 7, 2026 | SELL | $382.1K |
Hampton Malcolm Garret Director Jun 16, 2026 | AWARD | 20,000 sh |
Stein Jeffrey Director Jun 16, 2026 | AWARD | 20,000 sh |
ROSEN TERRY J Director Jun 16, 2026 | AWARD | 20,000 sh |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | -$1.16 | -$1.47–-$0.83 | -3.7% | $20.1M |
| Next Q | -$1.24 | -$1.41–-$1.04 | -7.4% | $9.2M |
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Short side
FINRA· Oct 30, 2026SecBot reports
13 filings · 1 bullish · 4 bearish · 1 mixed · 7 neutral- NEUTRAL INST-CLUSTERNov 3, 2026
Four institutional asset managers added to their IDYA positions in Q3 2026, collectively…
The institutional buying is modest in scale relative to the $3.2B market cap and is not corroborated by insider buying (confluence score 11/100, divergent). Monitor the upcoming FDA decision on…
- NEUTRAL 8-KNov 3, 2026
The company completed its NDA submission for darovasertib in metastatic uveal melanoma and…
The NDA submission for darovasertib is the key near-term catalyst; FDA review under RTOR could yield a decision in H1 2027. The OptimUM-010 closure removes a cash drain and signals capital…
- BEARISH 144Oct 6, 2026
CEO Yujiro Hata filed a Form 144 notice of intent to sell shares of IDEAYA Biosciences, covering…
Monitor for actual Form 4 filings to confirm sales; the large CEO sale notice creates near-term overhang. Watch for any concurrent corporate events (earnings, data readouts) that may have motivated…
- NEUTRAL 8-KAug 4, 2026
IDEAYA Biosciences reported Q2 2026 results with a net loss of $112.5M ($-1.22/share), a wider…
The Q2 print itself is a non-event for a pre-revenue biotech, the wider loss was expected given rising trial costs. The key catalysts are the darovasertib NDA filing (H2 2026) and data readouts at…
All IDYA filing & press-release reports (13)
- INST-CLUSTER reportNov 3, 2026
- 8-K reportNov 3, 2026
- 144 reportOct 6, 2026
- 8-K reportAug 4, 2026
- 8-K reportJun 23, 2026
- 8-K reportJun 10, 2026
- 424B5 reportJun 9, 2026
- 424B5 reportJun 8, 2026
- 8-K reportJun 3, 2026
- 8-K reportMay 5, 2026
- 424B5 reportMay 5, 2026
- 8-K reportApr 13, 2026
- 8-K reportApr 9, 2026